Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176449 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Bupropion SR and Placebo for Smoking Cessation
A Phase 4 study of Tobacco Use Disorder, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT00176449: Completed Phase 4 study of Tobacco Use Disorder, sponsored by University of Maryland, Baltimore.
NCT00176449 is a Phase 4 study of Tobacco Use Disorder that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 52 participants, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00176449, a Phase 4 study of Tobacco Use Disorder, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine whether the adjunctive use of bupropion SR in the context of a psychoeducational program modified for people with schizophrenia might improve the likelihood of successful abstinence in this population. If bupropion SR is effective for reducing cigarette smoking, then it will be important to determine if decreased nicotine intake is associated with a worsening of psychotic, anxiety or depressive symptoms. In addition, it would be important to determine the effect that a reduction in nicotine stimulation would have on patient's cognitive functioning, as nicotinic receptors have been shown to regulate attention and memory function, and it is hypothesized that these functions are normalized by acute nicotine administration in people with schizophrenia
Conditions Studied
Interventions
- DRUG Placebo Oral Tablet
- DRUG Bupropion SR
Study Locations (1)
Maryland
- Maryland Psychiatric REsearch Center - Catonsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2001-04 |
| Est. Completion | 2005-12 |
| Phase | Phase 4 |
What the finished NCT00176449 record still lists
NCT00176449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT00176449 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00176449 about?
NCT00176449 is a clinical study titled "A Comparison of Bupropion SR and Placebo for Smoking Cessation". The purpose of this study is to examine whether the adjunctive use of bupropion SR in the context of a psychoeducational program modified for people with schizophrenia might improve the likelihood of successful abstinence in this population. If bupropion SR is effective for reducing cigarette smokin...
What is the current status of trial NCT00176449?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2001-04. Estimated completion is 2005-12.
What conditions does trial NCT00176449 study?
This clinical trial studies the following conditions: Tobacco Use Disorder.
What interventions are being tested in trial NCT00176449?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Bupropion SR (DRUG).
Who is sponsoring clinical trial NCT00176449?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00176449 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00176449's enrollment target sits among peer trials
52 53rd of 70 higher than 18 of 70 other Tobacco Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Beta-Adrenergic Modulation of Drug Cue Reactivity
RECRUITING · Phase 4
-
E-cigarette Cessation in Adults Who Co-use Cannabis
RECRUITING · Phase 4
-
Varenicline and Combined NRT for Smoking Cessation
ACTIVE NOT RECRUITING · Phase 4
-
Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence
COMPLETED · Phase 4
-
Varenicline Effects In Schizophrenic Smokers
COMPLETED · Phase 4
-
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia